Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Fosamax in Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Spinal Cord Injury Association (ASIA) A or American Spinal Cord Injury Association (ASIA) B Spinal Cord Injury~Exclusion Criteria:~* History of hypersensitivity to alendronate or other bisphosphonates~* esophageal abnormality~* inability to sit/stand upright for 30 minutes~* creatinine clearance less than 35 milliliters/minute~* hypothyroidism~* malignancy~* pregnancy~* prolonged steroid use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Fosamax (Type: ACTIVE_COMPARATOR): Fosamax at 70 mgs q weekly by mouth for the duration of the study.
- Placebo Sugar Pill (Type: PLACEBO_COMPARATOR): Double blind study using Fosamax versus placebo. Placebo is an inactive drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).